American Journal of Physiology Biochemistry and Pharmacology, 2023
VOL 13, NO. 12, PAGE 01-02

COMMENTARY

Open Access

The Role of Pharmacovigilance in Post-Marketing Drug Safety Monitoring

Guan Xu*

Department of Pharmacology, Fudan University, Shanghai, China

ARTICLE HISTORY
Received: 27-Nov-2023, Manuscript No. AJPBP-24-124127;
Editor assigned: 30-Nov-2023, PreQC No. AJPBP-24-124127 (PQ);
Reviewed: 14-Dec-2023, QC No. AJPBP-24-124127;
Revised: 21-Dec-2023, Manuscript No. AJPBP-24-124127 (R);
Published: 28-Dec-2023

Description

In the field of medicine, the development and approval of new drugs mark significant milestones. However, ensuring the safety of these drugs is an on-going process that extends far beyond the initial stages of research and clinical trials. Post-marketing surveillance, facilitated by pharmacovigilance, plays a pivotal role in identifying and addressing potential safety concerns associated with pharmaceutical products. This article discusses about the importance of monitoring and assessing the safety of drugs post-marketing and delves into the indispensable role that pharmacovigilance plays in safeguarding public health [1].

The drug approval process

Before a drug is granted approval for marketing and distribution, it undergoes rigorous testing through preclinical and clinical trials. These trials aim to establish the drug's efficacy, safety profile, and potential side effects. Despite these extensive evaluations, certain rare or long-term adverse effects may only become apparent when the drug is introduced to a larger, more diverse population.

The need for post-marketing surveillance

Post-marketing surveillance is essential for several reasons. Firstly, clinical trials often have limitations, including a relatively small sample size and a limited duration. This makes it difficult to capture the full spectrum of potential adverse effects that may manifest in a broader population over an extended period. Secondly, certain adverse reactions may only become evident after a drug interacts with other medications or in specific patient populations not well-represented in initial trials, such as pregnant women or the elderly [2,3].

Pharmacovigilance, derived from the Greek words "pharmakon" (drug) and "vigilare" (to keep watch), encompasses the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. It is a systematic process that involves monitoring the safety of drugs throughout their lifecycle, from approval to post-marketing[4].

Detecting Adverse Drug Reactions (ADRs)

One of the primary objectives of pharmacovigilance is to detect adverse drug reactions (ADRs) promptly. Healthcare professionals, patients, and pharmaceutical companies all play integral roles in reporting suspected ADRs. This collaborative approach allows for the collection of real-world data that contributes to a more comprehensive understanding of a drug's safety profile [5,6].

Signal detection and evaluation

Pharmacovigilance employs advanced data analysis techniques to identify potential safety signals. A signal is any information that suggests a new hazard or a change in the frequency or severity of a known hazard. Once a signal is detected, it undergoes thorough evaluation to determine its clinical significance. This process may involve analyzing patient data, conducting epidemiological studies, and reviewing relevant literature [7].

Regulatory authorities and pharmacovigilance

Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established pharmacovigilance systems to monitor and assess drug safety. These agencies work collaboratively with healthcare professionals, industry stakeholders, and the public to ensure a robust and transparent system for

Contact: Guan Xu Email: XUg123@tmpb.cn

reporting and evaluating potential safety concerns.

Preventing harm and enhancing patient safety

The ultimate goal of pharmacovigilance is to prevent harm and enhance patient safety. When significant safety concerns arise, regulatory authorities may take various actions, including updating product labels, issuing warnings, or, in extreme cases, removing a drug from the market. These measures are essential to protect the public and ensure that the benefits of a drug outweigh its risks [8,9].

The importance of monitoring and assessing the safety of drugs post-marketing cannot be overstated. While preclinical and clinical trials provide valuable insights into a drug's safety profile, post-marketing surveillance through pharmacovigilance is crucial for identifying and addressing unforeseen adverse effects in real-world settings. The collaborative efforts of healthcare professionals, patients, and regulatory authorities contribute to a comprehensive and dynamic system that prioritizes public health and ensures the ongoing safety of pharmaceutical products. As medical science advances and new drugs continue to emerge, the vigilance and commitment to pharmacovigilance will remain integral to safeguarding the well-being of individuals and communities worldwide [10].

References

[1] Gmackenzie SG, Lippman A. An investigation of report bias in a case-control study of pregnancy outcome. Am J Epidemiol 1989;129(1):65-75.

[2] Sarker A, Ginn R, Nikfarjam A, O'Connor K, Smith K, Jayaraman S, et al. Utilizing social media data for pharmacovigilance: A review. J Biomed Inform 2015;54:202-212.

[3] Rahman SZ. Concept of materiovigilance in Unani medicine. Bangladesh J Med Sci 2019;18(1):5-6.

[4] Rahman SZ, Khan RA, Gupta V, Uddin M. Pharmacoenvironmentology–A component of pharmacovigilance. Environ Health 2007;6(1):1-3.

[5] Ruhoy IS, Daughton CG. Beyond the medicine cabinet: An analysis of where and why medications accumulate. Environ Int 2008;34(8):1157-1169.

[6] Holm G, Snape JR, Murray-Smith R, Talbot J, Taylor D, Sörme P, et al. Implementing ecopharmacovigilance in practice: Challenges and potential opportunities. Drug Saf 2013;36:533-546.

[7] Lexchin J. Drug withdrawals from the Canadian market for safety reasons, 1963–2004. Cmaj 2005;172(6):765-767.

[8] Neil Mc JJ, Piccenna L, Ronaldson K, Ioannides-Demos LL. The value of patient-centred registries in phase IV drug surveillance. Pharmaceutical Medicine. 2010;24:281-288.

[9] Zippel C, Bohnet-Joschko S. Post market surveillance in the german medical device sector–current state and future perspectives. Health Policy 2017;121(8):880-886.

[10] Bergström CA, Andersson SB, Fagerberg JH, Ragnarsson G, Lindahl A. Is the full potential of the biopharmaceutics classification system reached?. Eur J Pharm Sci 2014;57:224-231.